Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial Meeting Abstract
| Authors: | Jhaveri, K. L.; Goldman, J. W.; Hurvitz, S. A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J. R.; Yang, E. S. H.; Spanggaard, I.; Reid, S. A.; Burkard, M. E.; Prat, A.; Loi, S.; Crown, J.; Hanker, A.; Ma, C. X.; Bose, R.; Eli, L. D.; Wildiers, H. |
| Abstract Title: | Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300086 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.1028 |
| Notes: | Meeting Abstract: 1028 -- Meeting also held virtually -- Source: Wos |
